JAMA Pediatrics


Media advisory: To contact corresponding author Marsha Campbell-Yeo, Ph.D., email Terry Murray-Arnold at [email protected]. The full study and editorial are linked to this news release.

Want to embed a link to this study in your story? This full-text link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/2721241?guestAccessKey=34c29b3e-c3a2-4648-8f01-47c06c2b67ab

Bottom Line: Neonatal abstinence syndrome describes symptoms (including jitteriness, high-pitched crying, sweating and diarrhea) that primarily occur in newborns exposed to opioids during pregnancy. Finding an optimal drug therapy to treat newborns for neonatal abstinence syndrome may reduce the length of treatment and hospital stay. This study analyzed combined results from 18 randomized clinical trials that included morphine, the standard of care in most hospitals, and other medications to treat newborns for neonatal abstinence syndrome. Buprenorphine was associated with the shortest length of treatment but there were considerable limitations in the findings and a large trial is required for wide-scale adoption.

Author: Marsha Campbell-Yeo, Ph.D., Dalhousie University School of Nursing, Halifax, Nova Scotia, Canada, and coauthors 


Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email[email protected].